References

Bainbridge, M. N., W. Wiszniewski, D. R. Murdock, J. Friedman, C. Gonzaga-Jauregui, I. Newsham, J. G. Reid, J. K. Fink, M. B. Morgan, M. C. Gingras, D. M. Muzny, L. D. Hoang, S. Yousaf, J. R. Lupski, and R. A. Gibbs. 2011. Whole-genome sequencing for optimized patient management. Science Translational Medicine 3(87):87re3.

Bansal, V., R. Tewhey, E. J. Topol, and N. J. Schork. 2011. The next phase in human genetics. Nature Biotechnology 29(1):38–39.

Bloss, C. S., N. J. Schork, and E. J. Topol. 2011. Effect of direct-to-consumer genomewide profiling to assess disease risk. New England Journal of Medicine 364(6):524–534.

Boguski, M. S., R. Arnaout, and C. Hill. 2009. Customized care 2020: How medical sequencing and network biology will enable personalized medicine. F1000 Biology Reports 1:73.

Brandt, J. T., S. L. Close, S. J. Iturria, C. D. Payne, N. A. Farid, C. S. Ernest, 2nd, D. R. Lachno, D. Salazar, and K. J. Winters. 2007. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis 5(12):2429–2436.

Bustamante, C. D., E. G. Burchard, and F. M. De la Vega. 2011. Genomics for the world. Nature 475(7355):163–165.

Christensen, C. M. 1997. The innovator’s dilemma: When new technologies cause great firms to fail. Cambridge, MA: Harvard Business Press.

Coates, R., M. Williams, S. Melillo, and J. Gudgeon. 2011. Genetic testing for Lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives. PLoS Currents 3:RRN1246.

Collins, F. 2008. Departing U.S. genome institute director takes stock of personalized medicine. Science 320(5881):1272.

EGAPP (Evaluation of Genomic Applications in Practice and Prevention). 2009. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in Medicine 11(1):15–20.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 65
References Bainbridge, M. N., W. Wiszniewski, D. R. Murdock, J. Friedman, C. Gonzaga-Jauregui, I. Newsham, J. G. Reid, J. K. Fink, M. B. Morgan, M. C. Gingras, D. M. Muzny, L. D. Hoang, S. Yousaf, J. R. Lupski, and R. A. Gibbs. 2011. Whole-genome sequencing for optimized patient management. Science Translational Medicine 3(87):87re3. Bansal, V., R. Tewhey, E. J. Topol, and N. J. Schork. 2011. The next phase in human genetics. Nature Biotechnology 29(1):38–39. Bloss, C. S., N. J. Schork, and E. J. Topol. 2011. Effect of direct-to-consumer genomewide profiling to assess disease risk. New England Journal of Medicine 364(6):524–534. Boguski, M. S., R. Arnaout, and C. Hill. 2009. Customized care 2020: How medical sequenc- ing and network biology will enable personalized medicine. F1000 Biology Reports 1:73. Brandt, J. T., S. L. Close, S. J. Iturria, C. D. Payne, N. A. Farid, C. S. Ernest, 2nd, D. R. Lachno, D. Salazar, and K. J. Winters. 2007. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis 5(12):2429–2436. Bustamante, C. D., E. G. Burchard, and F. M. De la Vega. 2011. Genomics for the world. Nature 475(7355):163–165. Christensen, C. M. 1997. The innovator’s dilemma: When new technologies cause great firms to fail. Cambridge, MA: Harvard Business Press. Coates, R., M. Williams, S. Melillo, and J. Gudgeon. 2011. Genetic testing for Lynch syn- drome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives. PLoS Currents 3:RRN1246. Collins, F. 2008. Departing U.S. genome institute director takes stock of personalized medi- cine. Science 320(5881):1272. EGAPP (Evaluation of Genomic Applications in Practice and Prevention). 2009. Recommenda- tions from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in Medicine 11(1):15–20. 65

OCR for page 65
66 INTEGRATING LARGE-SCALE GENOMIC INFORMATION Gollust, S. E., E. S. Gordon, C. Zayac, G. Griffin, M. F. Christman, R. E. Pyeritz, L. Wawak, and B.A. Bernhardt. 2011. Motivations and perceptions of early adopters of personalized genomics: Perspectives from research participants. Public Health Genomics 15(1):22–30. Gong, I. Y., R. G. Tirona, U. I. Schwarz, N. Crown, G. K. Dresser, S. Larue, N. Langlois, A. Lazo-Langner, G. Zou, D. M. Roden, C. M. Stein, M. Rodger, M. Carrier, M. Forgie, P. S. Wells, and R. B. Kim. 2011. Prospective evaluation of a pharmacogenetics- guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118(11):3163–3171. Green, E. D., and M. S. Guyer. 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470(7333):204–213. Hagenkord, J. M., F. A. Monzon, S. F. Kash, S. Lilleberg, Q. Xie, and J. A. Kant. 2010. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: Performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. Journal of Molecular Diagnostics 12(2):184–196. Hughes, A. R., W. R. Spreen, M. Mosteller, L. L. Warren, E. H. Lai, C. H. Brothers, C. Cox, A. J. Nelsen, S. Hughes, D. E. Thorborn, B. Stancil, S. V. Hetherington, D. K. Burns, and A. D. Roses. 2008. Pharmacogenetics of hypersensitivity to abacavir: From PGx hypothesis to confirmation to clinical utility. The Pharmacogenomics Journal 8(6):365–374. Jaeken, J. 2011. Congenital disorders of glycosylation (CDG): It’s (nearly) all in it! Journal of Inherited Metabolic Disease 34(4):853–858. Jones, S. J., J. Laskin, Y. Y. Li, O. L. Griffith, J. An, M. Bilenky, Y. S. Butterfield, T. Cezard, E. Chuah, R. Corbett, A. P. Fejes, M. Griffith, J. Yee, M. Martin, M. Mayo, N. Melnyk, R. D. Morin, T. J. Pugh, T. Severson, S. P. Shah, M. Sutcliffe, A. Tam, J. Terry, N. Thiessen, T. Thomson, R. Varhol, T. Zeng, Y. Zhao, R. A. Moore, D. G. Huntsman, I. Birol, M. Hirst, R. A. Holt, and M. A. Marra. 2010. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biology 11(8):R82. Kohane, I. S., K. D. Mandl, P. L. Taylor, I. A. Holm, D. J. Nigrin, and L. M. Kunkel. 2007. Medicine: Reestablishing the researcher–patient compact. Science 316(5826):836–837. Lindhurst, M. J., J. C. Sapp, J. K. Teer, J. J. Johnston, E. M. Finn, K. Peters, J. Turner, J. L. Cannons, D. Bick, L. Blakemore, C. Blumhorst, K. Brockmann, P. Calder, N. Cherman, M. A. Deardorff, D. B. Everman, G. Golas, R. M. Greenstein, B. M. Kato, K. M. Keppler-Noreuil, S. A. Kuznetsov, R. T. Miyamoto, K. Newman, D. Ng, K. O’Brien, S. Rothenberg, D. J. Schwartzentruber, V. Singhal, R. Tirabosco, J. Upton, S. Wientroub, E. H. Zackai, K. Hoag, T. Whitewood-Neal, P. G. Robey, P. L. Schwartzberg, T. N. Darling, L. L. Tosi, J. C. Mullikin, and L. G. Biesecker. 2011. A mosaic activating muta- tion in AKT1 associated with the Proteus syndrome. New England Journal of Medicine 365(7):611–619. Lohmueller, K. E., A. R. Indap, S. Schmidt, A. R. Boyko, R. D. Hernandez, M. J. Hubisz, J. J. Sninsky, T. J. White, S. R. Sunyaev, R. Nielsen, A. G. Clark, and C. D. Bustamante. 2008. Proportionally more deleterious genetic variation in European than in African populations. Nature 451(7181):994–997. Lupski, J. R., J. G. Reid, C. Gonzaga-Jauregui, D. Rio Deiros, D. C. Chen, L. Nazareth, M. Bainbridge, H. Dinh, C. Jing, D. A. Wheeler, A. L. McGuire, F. Zhang, P. Stankiewicz, J. J. Halperin, C. Yang, C. Gehman, D. Guo, R. K. Irikat, W. Tom, N. J. Fantin, D. M. Muzny, and R. A. Gibbs. 2010. Whole-genome sequencing in a patient with Charcot- Marie-Tooth neuropathy. New England Journal of Medicine 362(13):1181–1191. Lyssenko, V., A. Jonsson, P. Almgren, N. Pulizzi, B. Isomaa, T. Tuomi, G. Berglund, D. Altshuler, P. Nilsson, and L. Groop. 2008. Clinical risk factors, DNA variants, and the development of type 2 diabetes. New England Journal of Medicine 359(21):2220–2232. Mardis, E. R. 2006. Anticipating the 1,000 dollar genome. Genome Biology 7(7):112.

OCR for page 65
67 REFERENCES Ned, R. M. 2010. Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: Current evidence and test availability. Application: Pharmacogenomics. PLoS Currents 2:RRN1180. Nelson, D. L., and R. A. Gibbs. 2009. X-cess of variants in XLMR. Nature Genetics 41(5):510–512. Ng, S. B., K. J. Buckingham, C. Lee, A. W. Bigham, H. K. Tabor, K. M. Dent, C. D. Huff, P. T. Shannon, E. W. Jabs, D. A. Nickerson, J. Shendure, and M. J. Bamshad. 2010. Exome sequencing identifies the cause of a Mendelian disorder. Nature Genetics 42(1):30–35. PCAST (President’s Council of Advisors on Science and Technology). 2010. Realizing the full potential of health information technology to improve healthcare for Americans: The path forward. December 8. Available at http://www.whitehouse.gov/sites/default/files/ microsites/ostp/pcast-health-it-report.pdf (accessed October 15, 2011). Peat, R. A., J. M. Smith, A. G. Compton, N. L. Baker, R. A. Pace, D. J. Burkin, S. J. Kaufman, S. R. Lamande, and K. N. North. 2008. Diagnosis and etiology of congenital muscular dystrophy. Neurology 71(5):312–321. Richards, C. S., S. Bale, D. B. Bellissimo, S. Das, W. W. Grody, M. R. Hegde, E. Lyon, and B. E. Ward. 2008. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genetics in Medicine 10(4):294–300. Ripatti, S., E. Tikkanen, M. Orho-Melander, A. S. Havulinna, K. Silander, A. Sharma, C. Guiducci, M. Perola, A. Jula, J. Sinisalo, M. L. Lokki, M. S. Nieminen, O. Melander, V. Salomaa, L. Peltonen, and S. Kathiresan. 2010. A multilocus genetic risk score for coronary heart disease: Case-control and prospective cohort analyses. Lancet 376(9750):1393–1400. Rope, A. F., K. Wang, R. Evjenth, J. Xing, J. J. Johnston, J. J. Swensen, W. E. Johnson, B. Moore, C. D. Huff, L. M. Bird, J. C. Carey, J. M. Opitz, C. A. Stevens, T. Jiang, C. Schank, H. D. Fain, R. Robison, B. Dalley, S. Chin, S. T. South, T. J. Pysher, L. B. Jorde, H. Hakonarson, J. R. Lillehaug, L. G. Biesecker, M. Yandell, T. Arnesen, and G. J. Lyon. 2011. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. American Journal of Human Genetics 89(1):28–43. Sloan, J. L., J. J. Johnston, I. Manoli, R. J. Chandler, C. Krause, N. Carrillo-Carrasco, S. D. Chandrasekaran, J. R. Sysol, K. O’Brien, N. S. Hauser, J. C. Sapp, H. M. Dorward, M. Huizing, B. A. Barshop, S. A. Berry, P. M. James, N. L. Champaigne, P. de Lonlay, V. Valayannopoulos, M. D. Geschwind, D. K. Gavrilov, W. L. Nyhan, L. G. Biesecker, and C. P. Venditti. 2011. Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria. Nature Genetics 43(9):883–886. St. Hilaire, C., S. G. Ziegler, T. C. Markello, A. Brusco, C. Groden, F. Gill, H. Carlson- Donohoe, R. J. Lederman, M. Y. Chen, D. Yang, M. P. Siegenthaler, C. Arduino, C. Mancini, B. Freudenthal, H. C. Stanescu, A. A. Zdebik, R. K. Chaganti, R. L. Nussbaum, R. Kleta, W. A. Gahl, and M. Boehm. 2011. NT5E mutations and arterial calcifications. New England Journal of Medicine 364(5):432–442. Teml, A., E. Schaeffeler, K. R. Herrlinger, U. Klotz, and M. Schwab. 2007. Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically guided dosing. Clinical Pharmacokinetics 46(3):187–208. Tewhey, R., V. Bansal, A. Torkamani, E. J. Topol, and N. J. Schork. 2011. The importance of phase information for human genomics. Nature Reviews Genetics 12(3):215–223. Torkamani, A., and N. J. Schork. 2008. Predicting functional regulatory polymorphisms. Bioinformatics 24(16):1787–1792. Torkamani, A., N. Kannan, S. S. Taylor, and N. J. Schork. 2008. Congenital disease SNPs target lineage specific structural elements in protein kinases. Proceedings of the National Academy of Sciences USA 105(26):9011–9016.

OCR for page 65
68 INTEGRATING LARGE-SCALE GENOMIC INFORMATION Worthey, E. A., A. N. Mayer, G. D. Syverson, D. Helbling, B. B. Bonacci, B. Decker, J. M. Serpe, T. Dasu, M. R. Tschannen, R. L. Veith, M. J. Basehore, U. Broeckel, A. Tomita- Mitchell, M. J. Arca, J. T. Casper, D. A. Margolis, D. P. Bick, M. J. Hessner, J. M. Routes, J. W. Verbsky, H. J. Jacob, and D. P. Dimmock. 2011. Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genetics in Medicine 13(3):255–262. Zhou, S. F. 2009. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clinical Pharmacokinetics 48(11):689–723.